ACADIA PHARMACEUTICALS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.21 USD | +0.94% |
|
+6.01% | -44.78% |
| 04-30 | UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating | MT |
| 04-23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,589 | 8,499 | 3,752 | 2,578 | 5,140 | 2,817 | - | - |
| Enterprise Value (EV) 1 | 5,892 | 7,867 | 3,231 | 2,161 | 4,702 | 2,210 | 1,956 | 1,525 |
| P/E ratio | -26.7 x | -29.9 x | -22.2 x | -11.9 x | -84.6 x | 27.1 x | 13.2 x | 9.47 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 19.4 x | 19.2 x | 7.75 x | 4.98 x | 7.08 x | 2.91 x | 2.6 x | 2.3 x |
| EV / Revenue | 17.4 x | 17.8 x | 6.67 x | 4.18 x | 6.47 x | 2.29 x | 1.8 x | 1.24 x |
| EV / EBITDA | -24.2 x | -27.7 x | -19.3 x | -9.75 x | -69.3 x | 21.3 x | 8.79 x | 4.02 x |
| EV / FCF | -38.7 x | -54.7 x | -25.5 x | -19 x | 282 x | 19.4 x | 8.02 x | 4.07 x |
| FCF Yield | -2.58% | -1.83% | -3.92% | -5.28% | 0.35% | 5.17% | 12.5% | 24.6% |
| Price to Book | 9.5 x | 13.6 x | 6.95 x | 6.44 x | 11.9 x | 4.64 x | 3.09 x | 2.19 x |
| Nbr of stocks (in thousands) | 154,025 | 158,978 | 160,756 | 161,931 | 164,180 | 165,203 | - | - |
| Reference price 2 | 42.78 | 53.46 | 23.34 | 15.92 | 31.31 | 17.05 | 17.05 | 17.05 |
| Announcement Date | 20-02-26 | 21-02-24 | 22-02-28 | 23-02-27 | 24-02-27 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 339.1 | 441.8 | 484.1 | 517.2 | 726.4 | 966.4 | 1,084 | 1,226 |
| EBITDA 1 | -243.8 | -283.7 | -167.1 | -221.6 | -67.83 | 103.8 | 222.4 | 379.6 |
| EBIT 1 | -246.5 | -286.6 | -170.4 | -223.6 | -73.38 | 106.4 | 214.1 | 329.9 |
| Operating Margin | -72.71% | -64.87% | -35.2% | -43.23% | -10.1% | 11.01% | 19.75% | 26.91% |
| Earnings before Tax (EBT) 1 | -234.4 | -281 | -167.5 | -213.4 | -51.04 | 109.1 | 232.3 | 347.1 |
| Net income 1 | -235.3 | -281.6 | -167.9 | -216 | -61.29 | 109.6 | 220.9 | 321.5 |
| Net margin | -69.38% | -63.74% | -34.67% | -41.76% | -8.44% | 11.34% | 20.38% | 26.22% |
| EPS 2 | -1.600 | -1.790 | -1.050 | -1.340 | -0.3700 | 0.6281 | 1.296 | 1.801 |
| Free Cash Flow 1 | -152.3 | -143.8 | -126.8 | -114 | 16.65 | 114.2 | 244 | 374.7 |
| FCF margin | -44.9% | -32.54% | -26.19% | -22.05% | 2.29% | 11.82% | 22.51% | 30.56% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 110.05% | 109.67% | 98.71% |
| FCF Conversion (Net income) | - | - | - | - | - | 104.26% | 110.46% | 116.54% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20-02-26 | 21-02-24 | 22-02-28 | 23-02-27 | 24-02-27 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 131.6 | 130.8 | 115.5 | 134.6 | 130.7 | 136.5 | 118.5 | 165.2 | 211.7 | 231 | 208.7 | 241.8 | 254 | 261.2 | 221.1 |
| EBITDA 1 | -13.73 | -44.12 | -112.1 | -33.04 | -30.36 | -45.57 | -53.16 | 4.803 | -56.05 | 36.58 | 10.08 | 34.59 | 42.04 | 22.49 | - |
| EBIT 1 | -15.3 | -44.66 | -113 | -33.65 | -30.87 | -46.06 | -53.58 | 3.037 | -57.78 | 34.94 | 6.32 | 33.07 | 38.06 | 30.99 | 59.7 |
| Operating Margin | -11.63% | -34.15% | -97.88% | -25.01% | -23.61% | -33.75% | -45.23% | 1.84% | -27.29% | 15.12% | 3.03% | 13.68% | 14.99% | 11.87% | 27% |
| Earnings before Tax (EBT) 1 | -14.79 | -42.9 | -112.6 | -33.57 | -26.42 | -40.89 | -44.94 | 6.343 | -52.14 | 39.7 | 9.107 | 35.79 | 35.79 | 27.49 | 59.7 |
| Net income 1 | -14.46 | -43.09 | -113.1 | -34.01 | -27.18 | -41.72 | -43.02 | 1.114 | -65.18 | 45.8 | 8.071 | 34.4 | 34.72 | 27.73 | 47.2 |
| Net margin | -10.98% | -32.96% | -97.91% | -25.28% | -20.8% | -30.57% | -36.32% | 0.67% | -30.79% | 19.82% | 3.87% | 14.23% | 13.67% | 10.62% | 21.35% |
| EPS 2 | -0.0900 | -0.2700 | -0.7000 | -0.2100 | -0.1700 | -0.2600 | -0.2700 | 0.0100 | -0.4000 | 0.2800 | 0.0554 | 0.1917 | 0.1987 | 0.1703 | 0.2800 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-08 | 22-02-28 | 22-05-04 | 22-08-08 | 22-11-02 | 23-02-27 | 23-05-08 | 23-08-02 | 23-11-02 | 24-02-27 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 697 | 632 | 521 | 417 | 439 | 606 | 861 | 1,292 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -152 | -144 | -127 | -114 | 16.7 | 114 | 244 | 375 |
| ROE (net income / shareholders' equity) | -39.9% | -42.5% | -28.7% | -45.9% | -14.7% | 21.9% | 28.4% | 27.2% |
| ROA (Net income/ Total Assets) | -35.6% | -36% | -22.6% | -33.5% | -9.17% | 16.4% | 25.9% | 15.6% |
| Assets 1 | 661.7 | 782.9 | 741.4 | 644 | 668.4 | 668.9 | 853.1 | 2,060 |
| Book Value Per Share 2 | 4.500 | 3.930 | 3.360 | 2.470 | 2.640 | 3.680 | 5.520 | 7.770 |
| Cash Flow per Share 2 | -1.030 | -0.8700 | -0.7800 | -0.7100 | 0.1000 | 1.070 | 1.310 | 3.560 |
| Capex 1 | 1.13 | 7.59 | 1.12 | - | 0.05 | 3.39 | 2.73 | 1.92 |
| Capex / Sales | 0.33% | 1.72% | 0.23% | - | 0.01% | 0.35% | 0.25% | 0.16% |
| Announcement Date | 20-02-26 | 21-02-24 | 22-02-28 | 23-02-27 | 24-02-27 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
17.05
USD
Average target price
28.79
USD
Spread / Average Target
+68.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.78% | 2.82B | |
| +20.92% | 42.68B | |
| -2.91% | 42.4B | |
| +45.32% | 40.04B | |
| -6.20% | 28.31B | |
| +7.85% | 24.94B | |
| -19.80% | 18.96B | |
| +30.17% | 12.3B | |
| -2.70% | 11.95B | |
| -2.83% | 11.55B |
- Stock Market
- Equities
- ACAD Stock
- Financials ACADIA Pharmaceuticals Inc.
